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PHeart Rhythm Disorders
umulative Experience of Azimilide-Associated
orsades de Pointes Ventricular Tachycardia in the
9 Clinical Studies Comprising the Azimilide Database
raig M. Pratt, MD, FACC,* Hussein R. Al-Khalidi, PHD,† Jose M. Brum, MD,†
ichael J. Holroyde, PHD,† Peter J. Schwartz, MD, FACC,‡ Stephen R. Marcello, MD, FACC,†
artin Borggrefe, MD, FACC,§ Paul Dorian, MD, FACC, A. John Camm, MD, FACC,¶
n behalf of the Azimilide Trials Investigators
ouston, Texas; Cincinnati, Ohio; Pavia, Italy; Mannheim, Germany; Toronto, Canada; and London, England
OBJECTIVES The purpose of this study was to assess the incidence, temporal characteristics, and risk factors
associated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.
BACKGROUND Azimilide dihydrochloride is a class III antiarrhythmic drug possessing Ikr and Iks
channel-blocking properties.
METHODS Oral azimilide (75 to 125 mg/day) was taken by 5,375 patients in 19 clinical trials conducted
at 775 international centers. Of 3,964 patients in double-blind studies, 1,427 had a history of
atrial fibrillation or other supraventricular arrhythmia, 510 had an implantable cardioverter-
defibrillator, and 2,027 were post-myocardial infarction patients with a left ventricular
ejection fraction 35%.
RESULTS The TdP occurred in 56 patients assigned to azimilide, was dose-related, and tended to occur
earlier with an azimilide-loading regimen. Forty-three percent of TdP patients had a QT
interval corrected by Bazett’s formula, for heart rate, (QTc) 500 ms at the time of or before
the TdP occurrence. Significant risk factors using logistic regression were increasing age,
female gender, diuretic use, and lack of aspirin use.
CONCLUSIONS Azimilide-associated TdP has characteristics and risk factors similar to other Ikr blockers.
However, there is a distinctive temporal profile. The TdP events are not concentrated in the
first week. The azimilide-associated TdP rate is 1% (95% confidence interval 0.78 to 1.35)
and is not increased in patients with low left ventricular ejection fraction, even in
women. (J Am Coll Cardiol 2006;48:471–7) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.075Cardiology Foundation
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ezimilide dihydrochloride is a Vaughan-Williams class
II antiarrhythmic drug that has been investigated in: 1)
trial fibrillation (AF) and other supraventricular ar-
hythmias (SVA); 2) adjunctive antiarrhythmic therapy in
atients with implantable cardioverter-defibrillators
ICD); and 3) post-myocardial infarction (MI) patients.
zimilide has both Ikr and Iks channel-blocking prop-
rties (1). Azimilide prolongs the time to the first
ymptomatic recurrence of AF and atrial flutter (2,3) and
ecreases the frequency of ICD therapies (4,5). Azimilide
id not have an adverse effect on mortality in post-MI
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006, accepted April 11, 2006.atients with a left ventricular ejection fraction (LVEF)
35% (6). It has been speculated that torsades de pointes
TdP) and ventricular tachycardia (VT) occur with Ikr
hannel blockers in part as a consequence of the reverse
ate-dependent action of these drugs, and the property of
ks channel block theoretically could be less likely proar-
hythmic (7). On the other hand, combining Ikr and Iks
lockade theoretically could be more likely to cause TdP
ompared with Ikr blockade alone because congenital
alfunction of Iks channels is considered a risk factor for
dP on therapy with Ikr blockers (8).
Accordingly, we analyzed all clinical trials (published
nd unpublished) in the azimilide database to assess the
revalence and characteristics of azimilide-associated
dP. The purpose of this report is to describe the
ose-related incidence, temporal characteristics, risk fac-
ors, and clinical consequences of azimilide-associated
dP.
ETHODS
linical studies. This database describes 5,375 patients
nrolled during the period 1994 to 2004 who received
ral doses (75 to 125 mg/day) of azimilide in 19 clinical
t
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Azimilide TdP Profile August 1, 2006:471–7rials (10 double-blind and 9 open-label) conducted at
75 international clinical centers. Of these patients,
,427 had a history of primarily paroxysmal or persistent
F or another SVA and were enrolled in double-blind,
lacebo-controlled SVA clinical trials, in which patients
ere administered azimilide using a 3-day, twice daily
oading regimen of 150 to 250 mg/day followed by a daily
aintenance regimen (75 to 125 mg/day) of half the
oading dose. Of these, 947 placebo and 1,222 azimilide-
able 2. Summary of All Double-Blind Studies (75 to 125 mg)
Study Acronym Indication Dose
Total
Patient
CD VA PL 37
75 mg 45
125 mg 46
HIELD VA PL 214
75 mg 220
125 mg 199
LIVE (PMI) VA PL 1,690
75 mg 336
100 mg 1,691
VA1 AF PL 79
100 mg 184
VA2 AF PL 124
75 mg 133
VA3 AF PL 125
100 mg 122
125 mg 93
VA4 AF PL 241
125 mg 241
-STAR AF PL 215
125 mg 216
-COMET-I AF PL 219
125 mg 227
-COMET-II AF PL 224
125 mg 211
verall PL 3,168
75 mg 734
100 mg 1,997
125 mg 1,233
All AZ 3,964
F  atrial fibrillation; ALIVE (PMI)  Azimilide Post-Infarct Survival Evaluation
Abbreviations and Acronyms
AF  atrial fibrillation
ALIVE  Azimilide Post-Infarct Survival Evaluation
CI  confidence interval
EC  event committee
ECG  electrocardiogram
ICD  implantable cardioverter-defibrillator
JTc  JT interval corrected by Bazett’s formula,
for heart rate
LVEF  left ventricular ejection fraction
MI  myocardial infarction
QTc  QT interval corrected by Bazett’s formula,
for heart rate
SI  site investigator
SVA  supraventricular arrhythmias-STAR  Azimilide Supraventricular Tachyarrhythmia Reduction; AZ  azimilide; I
nhibition Evaluation With Azimilide; SVA  supraventricular arrhythmia; VA  ventricreated patients continued in open-label SVA trials on
aily azimilide (75 to 125 mg/day). Additionally, 510
atients with an ICD and a history of VT/ventricular
able 1. Demographic Comparison of Patients With or
ithout TdP
TdP
(n  56)
No TdP
(n  5,319) p Value
ge (mean  SD, yrs) 69  10 62  11 0.0001
emale (%) 56% 28% 0.0001
VEF (mean, %) 40% 38% NS
YHA functional class
0/I 57% 68%
II/III 43% 32% 0.0271
rior MI 45% 51% NS
ypertension 70% 56% 0.0124
iabetes 21% 19% NS
oncomitant medication
Beta-blocker 57% 63% NS
Calcium channel blocker 29% 26% NS
ACE inhibitor 50% 63% NS
Aspirin 41% 63% 0.0013
Digoxin 59% 36% 0.0007
Statin 23% 36% NS
Diuretics 77% 49% 0.0001
CE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction;
I  myocardial infarction; NS  not statistically significant; NYHA  New York
eart Association; TdP  torsades de pointes.
Number
(%) of TdP
95% Confidence
Interval
Follow-Up
Period (Months)
0 (0.0) (0.0–9.5) 12
0 (0.0) (0.0–7.9)
2 (4.4) (0.5–14.8)
1 (0.5) (0.01–2.6) 12
2 (0.9) (0.1–3.3)
3 (1.5) (0.3–4.3)
1 (0.06) (0.01–0.3) 12
1 (0.3) (0.01–1.7)
6 (0.4) (0.1–0.8)
0 (0.0) (0.0–4.6) 9
3 (1.6) (0.3–4.7)
0 (0.0) (0.0–2.9) 9
0 (0.0) (0.0–2.7)
0 (0.0) (0.0–2.9) 6
2 (1.6) (0.2–5.8)
0 (0.0) (0.0–3.9)
0 (0.0) (0.0–1.5) 6
1 (0.4) (0.01–2.3)
0 (0.0) (0.0–1.7) 6
0 (0.0) (0.0–1.7)
0 (0.0) (0.0–1.7) 6
6 (2.6) (1.0–5.7)
0 (0.0) (0.0–1.6) 6
5 (2.4) (0.8–5.4)
2 (0.06) (0.01–0.23)
3 (0.4) (0.08–1.2)
11 (0.6) (0.3–1.0)
17 (1.4) (0.8–2.2)
31 (0.78) (0.5–1.1)
Myocardial Infarction); A-COMET  Azimilide Cardioversion Maintenance Trial;s
(Post-
CD  implantable cardioverter-defibrillator; PL  placebo; SHIELD  Shock
ular arrhythmia.
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August 1, 2006:471–7 Azimilide TdP Profilebrillation and 2,027 post-MI patients with an LVEF
35% were enrolled in 12-month, double-blind,
lacebo-controlled trials. In the ICD and post-MI trials,
atients received daily azimilide doses without any load-
ng regimen.
Thus, this analysis includes 3,964 patients assigned to
zimilide (75 to 125 mg/day) with a mean exposure of 214
median 223) days in placebo-controlled trials and 1,411
aking azimilide in open-label SVA (n  1,263) and ICD
n  148) trials. There were 6,445 patient-years of exposure
o azimilide. Of the 3,964 patients in double-blind studies,
,427 were in 7 SVA trials, 510 were in 2 ICD trials, and
,027 post-MI patients were in the Azimilide Post-Infarct
urvival Evaluation (ALIVE) trial (6). In the placebo-
ontrolled trials, there were 1,498 (38%) patients who had
heir first dose initiation in-hospital, and the remainder
ere outpatients.
Among a total of 3,168 placebo-assigned patients, 2 cases
f TdP (0.06%, 95% confidence interval [CI] 0.01 to 0.23)
ere documented. The focus of this article is on the 56
zimilide-assigned cases of TdP. A total of 31 azimilide-
ssociated TdP cases occurred in placebo-controlled trials
n  3,964), and 25 azimilide-associated TdP cases oc-
urred in open-label extension trials (n  1,411).
tatistical analysis. Continuous baseline characteristics are
resented as mean  SD and were compared using the
ilcoxon rank-sum test. All p values are two-sided. Cate-
orical variables were analyzed using the Pearson chi-square
est or Fisher exact test. The log-rank statistic was used to
nalyze time-to-TdP occurrence (9), and the Cochran-
rmitage trend test (10) was used to compare the TdP rates
er 100 patient-years of exposure. Univariate risk factor
nalyses for TdP occurrences were performed using the
isher exact test. Multivariate logistic regression analysis
as implemented using the risk factors for TdP identified in
he univariate analyses. A stepwise procedure was performed
o include risk factors in the model that met the 0.05
ignificance level as an entry criterion. A logistic regression
odel with selected significant risk factors was used to
stimate the adjusted odds ratios, 95% CIs, and p values.
djudication of TdP events. The diagnosis of torsades de
ointes was appropriate for episodes of polymorphic VT
omprising at least 2 cycles of ventricular complexes with
lternating electrical polarity and amplitude that were pre-
eded by pauses and excessive QT interval corrected by
azett’s formula, for heart rate, (QTc) prolongation. The
Tc reported uses the Bazett formula (11). All arrhythmic
vents in the double-blind trials that were documented by a
2-lead electrocardiogram (ECG) or ECG rhythm strip
ere adjudicated by an event committee (EC). Other cases
ere reported by the site investigator (SI) for studies
ithout EC (ALIVE and ICD open-label) and included
ven if ECG confirmation was not available. To be conser-
ative, all 56 cases of TdP that were reported by the EC
nd/or by the SI are included in the analysis. Of these 56
ases, 24 of them (12 double-blind and 12 open-label) had aoncurrence by both EC and SI, 17 cases (8 double-blind
nd 9 open-label) reported by SI alone (in those trials in
hich no EC was present or a strip was not available to send
o the EC) and 15 cases (11 double-blind and 4 open-label)
y EC alone. If available and when feasible, ICD electro-
rams were a source of documentation for the diagnosis of
dP, if pauses and excessive QTc prolongation preceded
igure 1. Time course of torsades de pointes (TdP) in double-blind (DB)
trial fibrillation (AF) trials, all of which required azimilide loading (17
ases), and in the open-label (OL) trials, only for those patients who were
n placebo during the DB phase (7 cases) (A). Time course of TdP in the
9 cases without loading by treatment indication (17 AF OL, 15 ICD, 7
ost-myocardial infarction [MI]) (B). Time course of TdP in patients with
ersus without loading in the DB trials (17 loaded, 14 not loaded) (C).ny polymorphic VT event.
RD
c
(
c
p
s
E
n
S
t
c
o
t
(
t
t
l
S
(
d
t
s
E
o
T
1
e
C
t
I
p
r
i
2
F
a
a
i
0
w
0
(
l
(
T
T
2
5
i
t
m
n
9
1
c
1
w
R
m
e
w
a
(
t
r
Q
m
(
o
0
T
A
I
A
O
*
474 Pratt et al. JACC Vol. 48, No. 3, 2006
Azimilide TdP Profile August 1, 2006:471–7ESULTS
emographics of patients. Azimilide-associated TdP oc-
urred in 56 of 5,375 (1%, 95% CI 0.78 to 1.35) patients
median azimilide exposure  366 days). The baseline
omparison of TdP patients to those without TdP is
resented in Table 1. The summary of all double-blind
tudy experience is listed in Table 2.
ffect of loading azimilide in SVA patients. There was
o significant difference in episodes of TdP that occurred in
VA trials (34 of 2,690) versus ICD/ventricular arrhythmia
rials (22 of 2,685). Although no formal statistical test was
onducted for the time course comparisons, the time courses
f the azimilide-associated TdP in the double-blind SVA
rials tended to occur earlier than in the open-label SVA
placebo roll-over patients) trials (Fig. 1A), possibly related
o the azimilide loading regimen in the double-blind SVA
rials. In patients administered daily azimilide doses without
oading, the time courses for TdP cases were similar for the
VA open-label, ICD, and post-MI patient populations
Fig. 1B). However, in patients administered daily azimilide
oses with a loading regimen, approximately two-thirds of
he TdP cases were clustered early in the double-blind
tudies (Fig. 1C).
ffect of azimilide dose and patient characteristics on the
ccurrence of TdP. The incidence of azimilide-associated
dP is dose related (Table 3). For azimilide doses of 75,
00, and 125 mg, the TdP rate per 100 patient-years
xposed was 0.28, 0.52, and 0.84, respectively (p  0.001,
ochran-Armitage trend test) (10). In patients adminis-
ered 75 mg/day without loading, the incidence of TdP in
CD patients, SVA (open-label) patients, and post-MI
atients was 0.44, 0.14, and 0.39 per 100 patient-years,
espectively. The increase in TdP rates with higher azimil-
de doses is more obvious in female than male patients (Fig.
A). The relationship of age to TdP incidence is shown in
igure 2B. Women have a higher TdP incidence than men
able 3. Distribution of TdP Cases by Treatment Indication and
Arrhythmia Treated Dose (mg)
Total No. of
Patients*
No. of
TdP (%)
TRIAL†
DB 75 133 0 (0.0)
100 306 5 (1.63)
125 988 12 (1.21)
OL 75 330 1 (0.30)
100 584 3 (0.51)
125 1,804 13 (0.72)
CD
DB 75 265 2 (0.75)
125 245 5 (2.04)
OL 125 417 8 (1.92)
LIVE (PMI) 75 336 1 (0.30)
100 1,691 6 (0.35)
verall 75 955 4 (0.42)
100 2,349 14 (0.60)
125 2,688 38 (1.41)Some patients are counted twice for exposure to more than 1 dose level. †Primarily atrial
DB  double-blind; OL  open-label; other abbreviations as in Table 2.t all ages. For example, women older than 75 years have
pproximately double the risk of TdP compared with men
n the same age group (4.0% of 250 vs. 2.2% of 318, p 
.2253). Women 65 years tend to have double the risk of
omen 65 years (2.6% of 912 vs. 1.0% of 602; p 
.0363). In the post-MI patient population with low LVEF
35%), the incidence of azimilide-associated TdP is very
ow (0.35%, 95% CI 0.14 to 0.71), even among women
0.7%, 95% CI 0.14 to 1.98).
emporal pattern of TdP. The 56 azimilide-associated
dP events occurred at a median time of 69 days (range 2 to
,155 days) after initial dosing, more than two-thirds (40 of
6) of which occurred more than 14 days after azimilide
nitiation. Only 7 of 56 (13%) of the TdP events occurred in
he first 3 days of azimilide exposure, 4 in women and 3 in
en. The time course of azimilide-associated TdP cases was
ot different for the 3 treatment indications (Fig. 1B).
The median time to TdP among placebo patients (n 
47) who started azimilide in the SVA open-label trials was
71 days (mean 277 days) after starting open-label trials as
ompared with patients in the double-blind AF trials (Fig.
A), with a median of 6 days (mean 40 days). This difference
as statistically significant with a log-rank p value 0.003.
elationship of QTc to TdP. Patients with a QTc 440
s at baseline (before randomization) were excluded from
ntry into the azimilide trials. During the study, patients
ith a QTc 525 ms were withdrawn from the study. In
ddition, patients in the ICD trials who had a wide QRS
QRS  120 ms) were excluded from entry or withdrawn if
heir JT interval corrected by Bazett’s formula, for heart
ate, (JTc) 320 ms or JTc 400 ms, respectively. Baseline
Tc of the 56 azimilide-associated TdP patients (mean 412
s) was similar to the QTc of the remaining 5,319 patients
mean 411 ms); however, the mean maximal QTc intervals
bserved were significantly different (532 vs. 489 ms; p 
.0013). The QTc outlier analysis is more revealing in that
e
Lower 95%
Confidence Interval
Upper 95%
Confidence Interval
Incidence per 100
Patient-Yrs
0.0 2.74 0.0
0.53 3.77 0.81
0.62 2.11 1.14
0.01 1.68 0.14
0.11 1.49 0.23
0.38 1.23 0.39
0.09 2.70 0.44
0.66 4.70 1.22
0.82 3.75 0.77
0.01 1.65 0.39
0.13 0.77 0.44
0.11 1.07 0.28
0.32 1.00 0.52
0.99 1.94 0.84Dosfibrillation.
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August 1, 2006:471–7 Azimilide TdP Profile3% of TdP patients had at least 1 ECG with a QTc 500
s before TdP, compared with 22% of non-TdP patients (p
0.0014). Furthermore, 27% of azimilide-assigned pa-
ients in whom TdP developed had at least 1 ECG with a
Tc 550 ms, compared with 6% of patients without TdP
igure 2. Incidence of torsades de pointes (TdP) by gender at each
zimilide dose (A). Frequency of TdP by gender and age distribution (B).
ercent of patients with and without TdP across different QTc ranges (C).
istribution of patients by maximum QTc and the risk for TdP (D).
bbreviations as in Figure 1.p  0.0001). There were 276 (5%) patients (189 in double-blind and 87 in open-label studies) who were
ithdrawn because of QTc prolongation. In none of these
atients did TdP develop.
There is a clear relationship between maximum QTc values
500 ms and the risk of a TdP developing. Figure 2C shows
he difference in percentage of patients with and without TdP
cross several QTc cuts, and Figure 2D illustrates a 5-fold
ncrease in the risk of TdP with a maximum QTc in the range
f 580 ms or higher.
A univariate analysis of risk factors to the azimilide-
ssociated TdP events is presented in Table 4. A multivariate
nalysis of TdP risk factors (excluding QTc because data were
ot available for 7 patients who experienced TdP) using a
ogistic regression model is presented in Table 5. The final
odel resulted in 4 significant risk factors: increasing age,
emale gender, diuretic use, and lack of aspirin use.
A total of 42 (75%) azimilide-associated TdP events oc-
urred in-hospital or resulted in hospitalization. Of the 56 TdP
atients, 4 died within 48 h (2 documented nonsustained cases
nd 2 investigator-reported “possible” TdP without ECG
ocumentation). A total of 1,329 (25%) patients (246 [16%]
omen and 1,038 [28%] men) were taking statins and aspirin
s concomitant medications. Among the 56 patients (30
omen and 26 men) who experienced TdP, only 7 (13%)
atients (1 woman and 6 men) were taking both a statin and
spirin as concomitant medications at the time of the event.
ISCUSSION
here were 56 cases of TdP in the 5,375 patients (1%, 95% CI
.78 to 1.35) assigned to azimilide (75 to 125 mg). Although
e acknowledging the heterogeneity issue in comparing 2
atabases, it is instructive to compare the clinical features of
zimilide-associated TdP with the published experience with
ther Ikr blockers (quinidine, sotalol, dofetilide). Azimilide-
ssociated TdP is similar in profile to Ikr blockers (12–19) in
hat: 1) it occurs more frequently in women and in elderly
atients; 2) it occurs more frequently with digitalis or diuretic
se; 3) there is an increased TdP risk with increased dose and
ith the use of a loading regimen; and 4) there is an association
etween TdP and maximum QTc.
Azimilide-associated TdP differs from published reports of
ther Ikr blockers in that: 1) the time course of TdP cases in
atients administered azimilide without a loading regimen is
ot concentrated early after azimilide initiation, with only 14%
f such TdP cases occurring10 days after initiation, whereas
1% of TdP cases occurred 180 days after initial azimilide
ssignment; 2) the overall azimilide-associated TdP rate of 1%
s low, given that50% of the patients receiving azimilide had
n LVEF 35%; 3) patients with TdP were less likely to be
aking aspirin; and 4) AF patients assigned to azimilide (most
ad a normal LVEF) had a low (1.3%, 95% CI 0.87 to 1.76)
dP rate, yet it was 4-fold higher than in a post-MI popula-
ion with depressed LVEF (0.35%, 95% CI 0.14 to 0.71).
These general comparisons are primarily focused on sotalol,ofetilide, and quinidine; the first two because they are used
c
v
f
c
w
a
a
a
0
a
m
c
o
T
i
a
a
c
d
l
m
e
i
e
t
(
r
o
O
(
r
b
r
I
m
9
a
r
a
c
T
o
s
t
i
p
w
s
c
a
r
o
p
a
rected
T
R
I
F
D
L
A
476 Pratt et al. JACC Vol. 48, No. 3, 2006
Azimilide TdP Profile August 1, 2006:471–7linically, the latter a historical comparison. Amiodarone has a
ery low prevalence of TdP in post-MI or congestive heart
ailure patients (20).
Like other Ikr blockers, azimilide-associated TdP is more
ommon in women, especially in the AF population, in which
omen represented 37% of the patients but 71% of the
zimilide-associated TdP events (13). That the time course of
zimilide-associated TdP cases is similar in women and men is
unique analysis not previously reported.
In the ALIVE, the azimilide-associated TdP rate was
.35% in a post-MI population with LVEF 35%. Sotalol-
ssociated TdP in doses of 160 to 320 mg/day is reported to be
ore prevalent in patients with a lower LVEF (12,13). In
ontrast to azimilide, dose adjustment for progressive degrees
f renal failure is required for both sotalol and dofetilide or the
dP rate increases. The time course of the appearance of TdP
s reported to be front-loaded with sotalol and dofetilide as well
s with quinidine-related TdP, occurring in the first week in
pproximately three-fourths of the cases (12,14–19,21). Non-
ardiac drugs may show sporadic torsades because of occasional
rug interactions (e.g., terfenadine), thus not showing a front-
oaded proarrhythmic profile (22). Temporal profiles of TdP
ay partially be explained by different degrees of early telem-
try monitoring. Dofetilide trials required mandatory inpatient
nitiation, including 3 days of telemetry monitoring, facilitating
arly detection (14–15).
Table 4. Univariate TdP Risk Factor Analysis
Risk Factor
TdP (%)*
(n  56)
No T
(n  5
Female 30 (2.0%) 1,48
Age (65 yrs) 43 (1.7%) 2,43
Max QTc  477 ms†‡ 34 (1.3%) 2,51
Max QTc  525 ms†‡ 13 (2.5%) 50
Baseline heart rate 60
beats/min
10 (0.8%) 1,22
Potassium level 4.0 meq/l 28 (1.7%) 1,65
Magnesium 1.5 meq/l 2 (1.8%) 10
Diuretic use 41 (1.6%) 2,49
Digoxin use 29 (1.6%) 1,74
Lack of aspirin 34 (1.6%) 2,06
Lack of statins 44 (1.3%) 3,45
Lack of aspirin and statins 49 (1.2%) 3,99
CHF 33 (1.1%) 3,08
Antiplatelet use 3 (0.5%) 62
*These are percentages of TdP among those who are at ris
(7 patients with TdP) had no QTc measurements during the s
measurements. §Median value. ¶Protocol withdrawal value.
CHF  congestive heart failure; QTc  QT interval cor
Table 2.
able 5. Multivariate TdP Risk Factor Analysis: Logistic
egression Model
Risk Factor
Adjusted Odds
Ratio
95% Confidence
Interval
Adjusted
p Value
ncreased age 2.9 (1.6–5.7) 0.0011
emale gender 2.1 (1.2–3.7) 0.0057
iuretic use 2.9 (1.6–5.5) 0.0005
ack of aspirin 2.4 (1.4–4.2) 0.0020bbbreviations as in Table 2.An additional observation of azimilide-associated TdP is
hat patients in the supraventricular arrhythmia population
double-blind), despite preserved LVEF, have a higher TdP
isk compared with patients in the post-MI (17 of 1,427 vs. 7
f 2,027, odds ratio 3.5, 95% CI 1.44 to 8.41, p  0.0056).
ne possible explanation is that AF studies required loading
23). Another probable explanation is that the sudden heart
ate slowing associated with termination of paroxysms of AF
y DC cardioversion in these studies (i.e., conversion to sinus
hythm) may increase the risk for TdP in this population (24).
n the ALIVE study, there was no difference in all-cause
ortality between azimilide and placebo (hazard ratio  1.0,
5% CI 0.82 to 1.22). This finding is robust in that there were
total of 488 deaths in all of the azimilide studies with hazard
atio  1.0 and 95% CI 0.83 to 1.19.
In the 2 trials with an ICD, all symptomatic or asymptom-
tic arrhythmic events detected by the devices that could be
onsidered an episode of TdP were counted. The incidence of
dP in the ICD studies in which these patients are continu-
usly monitored was 1.4% (95% CI 0.55 to 2.81). There were
imilar mortality rates in azimilide-treated (6.9%, 95% CI 5.7
o 7.6) and placebo-treated (6.8%, 95% CI 5.6 to 7.8) patients
n all placebo-controlled studies (7.4% vs. 7.1%, respectively, in
lacebo-controlled studies without ICDs).
The mean QTc at baseline before initiation of treatment
as not a predictor of TdP during treatment. This is not
urprising because baseline QTc prolongation was an exclusion
riterion. During treatment, 43% of patients having TdP had
t least 1 measurement of QTc 500 ms, suggesting that
outine ECG surveillance is useful. The standard cutoff points
f QTc of 500 and 550 ms used in clinical practice and
revious reports were significant predictors of azimilide-
ssociated TdP risk, consistent with published data on Ikr
Odds Ratio
(Exact 95% Confidence Interval) p Value†
3.0 (1.7–5.3) 0.0001
3.9 (2.1–7.9) 0.0001
2.3 (1.2–4.5) 0.0091
3.3 (1.6–6.4) 0.0008
0.7 (0.3–1.5) 0.5195
2.3 (1.3–4.0) 0.0031
1.8 (0.2–7.0) 0.3126
3.1 (1.7–6.0) 0.0001
2.2 (1.3–3.9) 0.0039
2.4 (1.4–4.4) 0.0013
2.0 (1.02–4.1) 0.0345
2.3 (1.04–6.1) 0.0413
1.0 (0.6–1.9) 1.0000
0.43 (0.1–1.3) 0.2050
veloping TdP. †Fisher exact test. ‡Note that 279 patients
f these, 203 had JTc measurements and 76 had no recorded
by Bazett’s formula, for heart rate; other abbreviations as indP
,319)
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August 1, 2006:471–7 Azimilide TdP ProfileAn additional observation from these analyses was the
ossible identification of 2 novel TdP risk factors. Admittedly,
oth may represent the play of chance. Patients not taking
spirin nor receiving statins had a significantly higher risk of
dP. Only 7 of 56 (13%) of patients with azimilide-associated
dP were taking both aspirin and statins, compared with 1,322
f 5,319 (25%) non-TdP patients. Although this may well be
chance finding, it may be related to the cardiovascular
enefits of these drugs, such as the anti-inflammatory effects
26–29) or the antiplatelet effects of aspirin (30). An alternative
practical) explanation is that the use of aspirin was lower in
atients with AF because of the use of warfarin.
onclusions. The incidence of TdP in azimilide-treated
atients is dose proportional, with a wide temporal distribution
f TdP events. Significant risk factors for TdP included female
ender, increasing age, diuretic use, and lack of aspirin use. The
dP rate is low (1%) even when the upper 95% confidence
imit (1.35%) is used and is unique in that there was no increase
zimilide-associated TdP risk in patients with a low LVEF.
his is true in the context that all azimilide studies had
xclusion criteria of baseline QTc 440 ms and patients were
ithdrawn when their QTc prolongation 525 ms during
rug therapy. If all patients with QTc 525 ms were with-
rawn, then the incidence of TdP could theoretically be
educed to 0.8% (95% CI 0.58 to 1.08). The predominance of
arly TdP cases seen with other Ikr blockers does not charac-
erize azimilide-associated TdP, except when loading doses of
zimilide are administered.
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